Inclusion and Exclusion Criteria
The eligibility criteria included(1)be a phase 2 or 3 clinical
randomized controlled trials (RCTs) for trunk and limbs of adults plaque
psoriasis and have at least 50 participants in each study;(2) topical
interventions included
were:tofacitinib, tapinarof,
benvitimod, calcipotriol, roflumilast, Cal/BD, betamethasone,
tacalcitol, halobetasol,HP/TAZ and vehicle(placebo);(3)studies reporting
at least one of efficacy outcomes(PGA0/1,IGA0/1,PASI75) and safety
outcomes (AEs,AEs leading to discontinuation of trial), all outcomes
were extracted at 4–12weeks.The exclusion criteria included case
reports, letters,retrospective studies, researches without data in
outcomes and lack usable date.